REXN News and Press, Rexahn Pharmaceuticals From 09/24/19

ROCKVILLE, Md., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Rexahn has engaged Oppenheimer & Co., Inc. as its financial advis...

Gainers:  Cambrex Corporation (NYSE: CBM ) +47% . Weight Watchers International (NASDAQ: WW ) +40% . Paratek Pharmaceuticals (NASDAQ: PRTK ) +35% . Owens & Minor (NYSE: OMI ) +29% . Match Group (NASDAQ: MTCH ) +27% . SolarEdge Technologies (NASDAQ: SEDG ) +24% . Guardant Hea...

Rexahn Pharmaceuticals (NYSEMKT: REXN ): Q2 GAAP EPS of -$0.61 beats by $0.34 . Cash and equivalents of $16.3M. Press Release More news on: Rexahn Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

ROCKVILLE, Md., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced financial results for the three and...